Pfizer will sell its remaining stake in British consumer healthcare group Haleon , the companies said on Tuesday.

GSK exited Kenya in 2023 as part of its restructuring and now supplies its medicines and vaccines through a third-party distributor. Be part of an exclusive group of enthusiasts! Get fresh content ...

Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth.

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer, sitting as a joint venture within GSK. It was then spun out of ...

The disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.

Haleon was formed in 2022 from a combination of GSK and Pfizer’s consumer-health units. Pfizer has been cutting down its stake in Haleon, most recently raising £2.5 billion through a block ...

and about average in terms of five-year share price performance - GSK stock hit a low of $29 after the Haleon plc (HLN) spinout, and traded as high as $44 in August last year. At the present time ...

Nairobi — UK drugmaker GlaxoSmithKline Limited (GSK) has rebranded to Haleon Kenya Limited, effective March 14, 2025. The rebrand comes after GSK transferred its consumer health business to ...

The total sale represents 7.3% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a ...